KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Receivables - Other: 2009-2025

Historic Receivables - Other for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $24.6 million.

  • Ionis Pharmaceuticals' Receivables - Other rose 37.26% to $24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 37.26%. This contributed to the annual value of $92.2 million for FY2024, which is 5.72% down from last year.
  • Ionis Pharmaceuticals' Receivables - Other amounted to $24.6 million in Q3 2025, which was down 53.20% from $52.6 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Receivables - Other ranged from a high of $142.4 million in Q3 2023 and a low of $5.1 million during Q1 2024.
  • Over the past 3 years, Ionis Pharmaceuticals' median Receivables - Other value was $28.0 million (recorded in 2023), while the average stood at $49.2 million.
  • In the last 5 years, Ionis Pharmaceuticals' Receivables - Other spiked by 2,042.35% in 2023 and then plummeted by 87.41% in 2024.
  • Ionis Pharmaceuticals' Receivables - Other (Quarterly) stood at $61.9 million in 2021, then tumbled by 58.74% to $25.5 million in 2022, then skyrocketed by 282.87% to $97.8 million in 2023, then declined by 5.72% to $92.2 million in 2024, then skyrocketed by 37.26% to $24.6 million in 2025.
  • Its Receivables - Other stands at $24.6 million for Q3 2025, versus $52.6 million for Q2 2025 and $39.7 million for Q1 2025.